Receptor News and Research

RSS

VEGF inhibitor fails to improve nonsquamous NSCLC overall survival

Adding motesanib to carboplatin–paclitaxel does not boost overall survival in patients with advanced nonsquamous non-small-cell lung cancer, including those with adenocarcinoma, say MONET1 investigators.

8 Aug 2012

Progression-free NSCLC survival boosted by dacomitinib

In patients with non-small-cell lunch cancer, dacomitinib confers a significant progression-free survival benefit over erlotinib across a range of clinical and molecular subgroups, the results of an international study indicate.

8 Aug 2012

Folate, excision biomarkers not predictive for small-cell lung cancer response

Biomarkers associated with the folate metabolism and excision repair pathways are not sufficiently prognostic to aid chemotherapy decisions for patients with extensive-stage disease small-cell lung cancer, results of a phase III trial show.

8 Aug 2012

GTx reports revenue of $1.6 million for second quarter 2012

GTx, Inc. today provided a Company update and reported financial results for the second quarter of 2012.

8 Aug 2012

Clovis Oncology reports net loss of $15.7 million for second quarter 2012

Clovis Oncology, Inc. today reported financial results for the second quarter 2012, and provided an update on the progress of its clinical development programs and expected milestones for the rest of the year.

8 Aug 2012

Studies identify genetic mutations that play important roles in startle disease

Two studies published in the Journal of Biological Chemistry identify genetic mutations that play important roles in the condition commonly referred to as startle disease. Startle disease is characterized by an exaggerated response to noise and touch, which can interfere with breathing, cause catastrophic falls and even result in death.

8 Aug 2012

Variations in RORA gene can lead to post-traumatic stress disorder

Investigators at Boston University School of Medicine (BUSM) and Veterans Affairs (VA) Boston Healthcare System have identified a new gene linked to post-traumatic stress disorder (PTSD).

8 Aug 2012

Leptin polymorphism combinations influence BMI in Chinese

The presence of genetic variants in both the leptin gene and the gene for its receptor may predispose Chinese individuals to obesity, report researchers.

7 Aug 2012

Surprise result in caffeine trial for Parkinson’s patients

Caffeine treatment may improve motor symptoms in patients with Parkinson’s disease, research suggests.

7 Aug 2012

Scientists discover biological marker that may help identify patients’ response to antidepressants

Scientists have discovered a biological marker that may help to identify which depressed patients will respond to an experimental, rapid-acting antidepressant. The brain signal, detectable by noninvasive imaging, also holds clues to the agent's underlying mechanism, which are vital for drug development, say National Institutes of Health researchers.

7 Aug 2012

Clinical trial targets breast cancer cells by injecting trastuzumab directly into the spinal fluid

In two to five percent of women with breast cancer, tumor cells migrate into the spinal fluid invading the tissue surrounding the brain and spinal cord called the meninges. While a rare complication, the condition is challenging because there is no agreed-upon standard of treatment, leaving little hope for patients affected. Northwestern Medicine- researchers are currently examining a novel approach to delivering an FDA approved drug that they hope will advance research for this type of cancer and lead to discoveries that may improve outcomes in the future.

7 Aug 2012

Novartis’ pasireotide offers symptom relief for patients with advanced neuroendocrine tumors

A researcher at Moffitt Cancer Center and his international team of colleagues have reported study results on a novel multireceptor-targeted somatostatin analogue called pasireotide (SOM230) manufactured by Novartis Pharma AG.

7 Aug 2012

Studies in mice reveal how mood-altering drugs may affect brain stem cells

Working with mice, Johns Hopkins researchers say they have figured out how stem cells found in a part of the brain responsible for learning, memory and mood regulation decide to remain dormant or create new brain cells. Apparently, the stem cells "listen in" on the chemical communication among nearby neurons to get an idea about what is stressing the system and when they need to act.

7 Aug 2012

Novel multireceptor-targeted somatostatin analogue found effective against neuroendocrine tumors

6 Aug 2012

New research center to expedite study of gene transfer approach

In an alliance aimed at bringing a new, personalized immunotherapy approach to patients with a wide variety of cancers, the University of Pennsylvania and Novartis announced today an exclusive global research and licensing agreement to further study and commercialize novel cellular immunotherapies using chimeric antigen receptor (CAR) technologies.

6 Aug 2012

Novartis, Penn partner to study and commercialize novel cellular immunotherapies for cancer

6 Aug 2012

First generic versions of Singulair receive FDA approval for treatment of asthma, allergies

The U.S. Food and Drug Administration today approved the first generic versions of Singulair (montelukast sodium) for use in adults and children to control asthma symptoms and to help relieve symptoms of indoor and outdoor allergies.

6 Aug 2012

Mechanism provides beneficial characteristics of energy-burning brown fat to white fat

Columbia University Medical Center (CUMC) researchers have identified a mechanism that can give energy-storing white fat some of the beneficial characteristics of energy-burning brown fat. The findings, based on studies of mice and of human fat tissue, could lead to new strategies for treating obesity and type 2 diabetes.

3 Aug 2012

Exercise benefits influenced by sRAGE levels in diabetes

Increased levels of the soluble form of the receptor for advanced glycation end products may underly the beneficial effects of exercise in patients with Type 2 diabetes, research shows.

3 Aug 2012

Investigational drug shows promise against most severe form of congenital hyperinsulinism

A pilot study in adolescents and adults has found that an investigational drug shows promise as the first potential medical treatment for children with the severest type of congenital hyperinsulinism, a rare but potentially devastating disease in which gene mutations cause insulin levels to become dangerously high.

2 Aug 2012

Receptor News and Research

VEGF inhibitor fails to improve nonsquamous NSCLC overall survival

Progression-free NSCLC survival boosted by dacomitinib

Folate, excision biomarkers not predictive for small-cell lung cancer response

GTx reports revenue of $1.6 million for second quarter 2012

Clovis Oncology reports net loss of $15.7 million for second quarter 2012

Studies identify genetic mutations that play important roles in startle disease

Variations in RORA gene can lead to post-traumatic stress disorder

Leptin polymorphism combinations influence BMI in Chinese

Surprise result in caffeine trial for Parkinson’s patients

Scientists discover biological marker that may help identify patients’ response to antidepressants

Clinical trial targets breast cancer cells by injecting trastuzumab directly into the spinal fluid

Novartis’ pasireotide offers symptom relief for patients with advanced neuroendocrine tumors

Studies in mice reveal how mood-altering drugs may affect brain stem cells

Novel multireceptor-targeted somatostatin analogue found effective against neuroendocrine tumors

New research center to expedite study of gene transfer approach

Novartis, Penn partner to study and commercialize novel cellular immunotherapies for cancer

First generic versions of Singulair receive FDA approval for treatment of asthma, allergies

Mechanism provides beneficial characteristics of energy-burning brown fat to white fat

Exercise benefits influenced by sRAGE levels in diabetes

Investigational drug shows promise against most severe form of congenital hyperinsulinism

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News